Stockscreener 앱 받기
0.99
2.94%
-0.03
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire
Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks
Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan
Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com
Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey
Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com
Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire
Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance
Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia
Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India
Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Mass. Biotech Receives FDA Approval - Streetwise Reports
Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa
Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India
What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News
Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks
FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times
FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan
BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biotech Stocks Facing FDA Decision In October 2024 - RTTNews
Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance
Five PDUFA dates on FDA’s October agenda - BioCentury
Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan
Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News
0.83%
1.03%
자본화:
|
볼륨(24시간):